MUTYH and cancer: [36] found a 1.8% rate of MUTYH monoallelic variants in a huge cancer cohort composed of CRC, BC, and endometrial cancer and concluded that there was no significant difference in the prevalence of monoallelic MUTYH pathogenic variants among cancer patients compared to controls.